Cancer vaccines seek to treat malignancies by approaches that induce presentation of tumor-associated antigens (TAAs) in contexts that elicit potent CD4+ and CD8+ T-cell responses and break the tolerance of the host immune system to tumor growth [1,2]. This evidence concerns the gene CD8A and neoplasm.